Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus

AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.

Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks

Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.

The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR

Apple, Novo Nordisk, RTX and FONAR are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Apple, Novo Nordisk & RTX

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Novo Nordisk A/S (NVO) and RTX Corporation (RTX), as well as a micro-cap stock FONAR Corporation (FONR).

Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.

Will Higher Expense Level Be a Woe for Humana in Q3 Earnings?

HUM's Q3 results are likely to suffer from decline in commercial fully-insured premiums and higher operating costs, partly offset by a well-performing Medicare business.

Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?

ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.

Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day.

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.

Sundeep Ganoria  headshot

Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.

Precision BioSciences to Report Q3 Earnings: What's in the Cards?

DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.

CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.

Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.

Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.

Vabysmo, Hemlibra Drive Roches Sales in Q3 & First 9 Months of 2024

RHHBY records impressive sales growth in Q3 and the first nine months of 2024 on the back of strong demand for Vabysmo, Hemlibra and Ocrevus.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.

Why Novo Nordisk (NVO) Dipped More Than Broader Market Today

Novo Nordisk (NVO) closed at $116.47 in the latest trading session, marking a -0.73% move from the prior day.

Kinjel Shah headshot

Is Pfizer's Attractive Valuation Enough to Invest in the Stock?

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

Ahan Chakraborty headshot

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.

Ahan Chakraborty headshot

NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.